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Abstract
Background: We use an approach based on Factor Analysis to analyze datasets generated for
transcriptional profiling. The method groups samples into biologically relevant categories, and
enables the identification of genes and pathways most significantly associated to each phenotypic
group, while allowing for the participation of a given gene in more than one cluster. Genes assigned
to each cluster are used for the detection of pathways predominantly activated in that cluster by
finding statistically significant associated GO terms. We tested the approach with a published
dataset of microarray experiments in yeast. Upon validation with the yeast dataset, we applied the
technique to a prostate cancer dataset.
Results: Two major pathways are shown to be activated in organ-confined, non-metastatic
prostate cancer: those regulated by the androgen receptor and by receptor tyrosine kinases. A
number of gene markers (HER3, IQGAP2 and POR1) highlighted by the software and related to
the later pathway have been validated experimentally a posteriori on independent samples.
Conclusion: Using a new microarray analysis tool followed by a posteriori experimental validation
of the results, we have confirmed several putative markers of malignancy associated with peptide
growth factor signalling in prostate cancer and revealed others, most notably ERRB3 (HER3). Our
study suggest that, in primary prostate cancer, HER3, together or not with HER4, rather than in
receptor complexes involving HER2, could play an important role in the biology of these tumors.
These results provide new evidence for the role of receptor tyrosine kinases in the establishment
and progression of prostate cancer.
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The phenotype of a cell is determined by its transcrip-
tional repertoire, a result of combinations of transcrip-
tional programs partly set during lineage determination
and partly activated in response to intrinsic and extrinsic
stimuli. Microarray hybridization experiments permit a
quantitative analysis of this transcriptional repertoire in
response to defined experimental conditions. A particu-
larly interesting case of study is given by the transcrip-
tional repertoire of human tumors. Here, the objective is
usually the search for cancer subtypes for individualized
prognosis and/or therapy. The questions most frequently
asked are whether samples can be automatically grouped,
in the absence of additional information, into biologi-
cally relevant phenotypes; and whether transcriptional
programs can be unveiled that can explain such pheno-
types. It must be noted that this situation (sample cluster-
ing and relevant gene extraction) is difficult mainly due to
three reasons [1]: the sparsity of the data (samples), the
high dimensionality of the feature (gene) space, and the
fact that many features are irrelevant or redundant (low
signal-to-noise ratio). It has been pointed out that, due to
the low signal-to-noise ratio, the quality and reliability of
clustering may degrade when using standard hierarchical
clustering algorithms or similar approximations [2]. Sim-
ilarly, model-based clustering methods encounter prob-
lems due to the sparsity of the set and its high
dimensionality, leading to overfitting during the density
estimation process [3]. Additional difficulties are encoun-
tered during the selection of features (genes) relevant to
the sample cluster structure, since most clustering meth-
ods produce non-overlapping gene clusters. This behav-
iour may distort the extraction of biologically relevant
genes in cases where expression patterns overlap several
classes of samples or experimental conditions, a reflection
of the dependence of the expression of most genes on
multiple signals and their participation in more than one
regulatory network.
Three main strategies have been taken in sample-based
clustering: unsupervised gene selection, interrelated clus-
tering and biclustering [1]. The first views gene selection
and sample clustering as basically independent processes,
the second dynamically uses the relationship between
gene and sample spaces to iteratively apply a clustering
and selection engine, while the third tries to cluster both
genes and samples at the same time in a reduced space.
For the first one, principal components analysis (PCA)[4]
has been proposed. PCA, a well known dimensionality
reduction technique, has been criticized because the sam-
ple projection in the low-dimensional space is not guaran-
teed to yield optimal sample partitions, particularly when
the fraction of relevant genes specific to each cluster is
small. As for the second approach, several novel methods
have been proposed recently based on various greedy fil-
tering techniques (for a review see [1]), but it has been
suggested that they may group the data based on local
decisions [1]. Finally, different biclustering methods have
also been applied to this situation [5-8], but a difficulty
with most biclustering tools is that they generate non-
overlapping partitions.
Here we apply Factor Analysis (FA) [9], a multivariate tool
related to PCA, coupled to clustering algorithms in sample
space, t-test scores in gene space and data mining proce-
dures. Q-mode (i.e. in sample space) FA is a latent varia-
ble modelling tool [9] that assumes that the observed
gene expression levels are the result of a linear combina-
tion of an unknown number of independent underlying
global transcriptional programs, called latent variables or
factors (Figure 1). The contribution of each factor to the
expression levels of the genes in each sample is given by
the elements of the loadings matrix (arrows in Figure 1).
Each sample contains, in addition, a given amount of
expression that cannot be modelled by the latent varia-
bles, for example due to the presence of noise. FA models
the covariance of a data matrix, as opposed to PCA, which
attempts to summarize the total variance. Covariance in
the mRNA expression levels has been shown to occur in
proteins involved in related pathways and functions, as
well as in proteins co-locating to the same organuli in the
cell, and may be indicative of common regulatory mecha-
nisms at the expression level[10]. By contrast, the specific
variance in the expression of a given gene, not associated
with the rest of the genes in the sample, is most likely
related to artefacts in the chip or in data handling. We
couple FA dimensionality reduction to clustering algo-
rithms [11] to obtain clusters in sample space. For gene
extraction, a multiple-testing corrected t-test (the so-called
q-value) is employed. Finally, the genes assigned to each
cluster are used for the detection of pathways predomi-
nantly activated in that cluster by finding statistically sig-
nificant the GO [12] or GenMAPP terms associated to
each cluster.
We first tested the approach by using a published dataset
of microarray experiments in yeast [13], and then applied
it to the analysis of human prostate cancer samples [14].
The yeast dataset is particularly relevant because the bio-
chemistry of S. cereviseae is relatively well understood in
comparison with other eukaryots, and the data set has
been previously analyzed with other clustering tech-
niques. From the application to the prostate cancer data-
set, a number of significant gene outcomes highlighted by
the algorithm have been corroborated experimentally a
posteriori by expression analysis on an independent set of
samples. The biological interpretation of the results lead
us to propose that two major pathways are predominantly
activated in organ-confined, non-metastatic prostatePage 2 of 18
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receptor tyrosine kinases. We close this paper by discuss-
ing the implications of these findings.
Results and Discussion
Testing FADA with the yeast expression dataset
Our procedure is coded in a software package, FADA. We
first tested FADA by analyzing the dataset of Gasch et al
[13], who studied the transcriptional responses of S. cere-
visiae to a variety of stress stimuli. The main results are in
Table 1, and the genes most significantly associated to the
clusters are in Table 1 of the Supporting Information. We
discuss in what follows only the most salient features of
the analysis for this set, corresponding to clusters 1, 2, 6,
8 and 16, from a biological viewpoint.
Cluster 1 encompasses responses to heat shock, DTT
(late), sorbitol (early response), stationary culture (late),
and overexpression of Msn2p and Msn4p. The significant
GO terms [12] automatically detected by FADA indicate
that this grouping is related to a common environmental
stress response (Table 1) (ESR or CER in the case of S. cer-
evisae, CESR in the case of S. pombe [13,15,16]). Inspec-
tion of the top selected genes (Table 1, supplementary
Graphical overview of Q-mode Factor Analysis (FA) [9]Figure 1
Graphical overview of Q-mode Factor Analysis (FA) [9]. Each sample is described by a vector xi, containing the expression lev-
els for all genes in the chip. The complete expression for all samples is contained in the matrix X = {xi}. The expression levels 
of each sample are assumed to be generated by a linear combination of a small number of underlying transcriptional programs, 
the latent (non-observable) variables, contained in the set of vectors {Fi}, forming matrix F. The relative contribution of each 
program is given by the thickness of the arrows connecting factors and samples, stored in variables lij, altogether forming the 
loading matrix L. Each lij element can be understood as the correlation coefficient between the expression levels of the sample 
and the corresponding latent variable. Residuals are kept in vectors {εi}, giving rise to matrix E. Note that small loadings con-
necting a given sample (i.e., X4 with the factor model implies large residuals.
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BMC Genomics 2005, 6:109 http://www.biomedcentral.com/1471-2164/6/109Table 1: Results of the analysis of the yeast dataset [13]. The different clusters found by FADA are shown, together with the significant 
GO terms associated to them. The samples belonging to each one of the clusters are also shown. The first column shows the cluster 
number; the second shows the conditions associated to that cluster; columns 3 to 5 show the Z-score of the GO terms associated to 
the cluster (see Methods) at the Cellular Component (CC), Biological Process (BP) and Molecular Function (MF) levels; columns 6 to 
8 show the corresponding GO terms.
C CONDITIONS Z(CC) Z(BP) Z(MF) GO(CC) GO(BP) GO(MF)
1 Heat_Shock_05_minutes_hs.1, Heat_Shock_10_minutes_hs.1
Heat_Shock_15_minutes_hs.1, Heat_Shock_20_minutes_hs.1
Heat_Shock_30_minutes_hs.1, Heat_Shock_40_minutes_hs.1
Heat_Shock_60_minutes_hs.1, Heat_Shock_80_minutes_hs.1
Heat_Shock_015_minutes_hs.2, Heat_Shock_030minutes_hs.2
heat_shock_17_to_37._20_minutes, 
heat_shock_21_to_37._20_minutes 
heat_shock_25_to_37._20_minutes, 
heat_shock_29_to_37._20_minutes 
heat_shock_33_to_37._20_minutes 29C_to_33C_._5_minutes, 
29C_to_33C_._15_minutes
29C_.1M_sorbitol_to_33C_._1M_sorbitol_._5_minutes
29C_.1M_sorbitol_to_33C_._1M_sorbitol_._15_minutes
29C_.1M_sorbitol_to_33C_._.NO_sorbitol_._5_minutes
dtt_240_min_dtt.2 1M_sorbitol_._5_min
1M_sorbitol_._15_min 1M_sorbitol_._30_min
1M_sorbitol_._45_min_ DBY7286_37degree_heat_._20_min
DBYmsn2.4._37degree_heat_._20_min
DBYmsn2.4_.real_strain._._37degrees_.20_min.
DBYyap1._37degree_heat_._20_min_.redo.
DBYyap1_._37degree_heat_.repeat., 
DBYyap1_._0.32_mM_H2O2_.20_min. 
Msn2_overexpression_.repeat.
Msn4_overexpression
3.25 5.39 1.16 nucleolus (325/
88;0.81E-006)
ribosome biog. & ass. 
(271/75; 0.57E-007) 
response to stress 
(214/52; 0.26E-003)
2 constant_0.32_mM_H2O2_.10_min._redo
constant_0.32_mM_H2O2_.20_min._redo
constant_0.32_mM_H2O2_.30_min._redo
constant_0.32_mM_H2O2_.40_min._rescan
constant_0.32_mM_H2O2_.50_min._redo
constant_0.32_mM_H2O2_.60_min._redo
1.5_mM_diamide_.5_min. 1.5_mM_diamide_.10_min.
1.5_mM_diamide_.20_min. 1.5_mM_diamide_.30_min.
1.5_mM_diamide_.40_min. 1.5_mM_diamide_.50_min.
1.5_mM_diamide_.60_min. 1.5_mM_diamide_.90_min.
DBY7286_._0.3_mM_H2O2_.20_min.
DBYmsn2msn4_.good_strain._._0.32_mM_H2O2
DBYmsn2.4_.real_strain._._0.32_mM_H2O2_.20_min.
DBYyap1._._0.3_mM_H2O2_.20_min.
0.39 9.71 11.40 protein catabolism 
(114/28; 0.74E-017) cell 
homeostasis (54/8; 
0.10E-003)
peptidase activity 
(125/25; 0.17E-012) 
oxidored. Act. (263/
30; 0.36E-008)
3 2.5 mM_DTT_045_min_dtt.1 2.5 mM_DTT_060_min_dtt.1
2.5 mM_DTT_090_min_dtt.1 2.5 mM_DTT_120_min_dtt.1
2.5 mM_DTT_180_min_dtt.1 dtt_120_min_dtt.2
6.55 2.53 1.86 endoplasmic ret. (353/
27; 0.11E-008)
4 constant_0.32_mM_H2O2_.80_min._redo
constant_0.32_mM_H2O2_.100_min._redo
constant_0.32_mM_H2O2_.120_min._redo
constant_0.32_mM_H2O2_.160_min._redo
1.25 0.63 1.58
5 37_deg_growth_ct.1 NA NA NA
6 Nitrogen_Depletion_8_h Nitrogen_Depletion_12_h
Nitrogen_Depletion_1_d Nitrogen_Depletion_2_d
Nitrogen_Depletion_3_d Nitrogen_Depletion_5_d
7.11 5.30 0.61 plasma membrane (197/
16; 0.86E-005)
extracellular region (19/
4; 0.85E-004)
transcription (225/15 
0.57E-003)
7 diauxic_shift_timecourse_18.5_h
diauxic_shift_timecourse_20.5_h YPD_6_h_ypd.2
YPD_8_h_ypd.2 YPD_10_h_ypd.2 YPD_12_h_ypd.2
YPD_1_d_ypd.2 YPD_2_d_ypd.2 YPD_3_d_ypd.2
YPD_5_d_ypd.2 YPD_stationary_phase_12_h_ypd.1
YPD_stationary_phase_1_d_ypd.1
YPD_stationary_phase_2_d_ypd.1
YPD_stationary_phase_3_d_ypd.1
YPD_stationary_phase_5_d_ypd.1
YPD_stationary_phase_7_d_ypd.1
YPD_stationary_phase_13_d_ypd.1
YPD_stationary_phase_22_d_ypd.1
YPD_stationary_phase_28_d_ypd.1
ethanol_vs._reference_pool_car.1
YP_ethanol_vs_reference_pool_car.2
9.91 #### 5.51 ribosome (368/126; 
0.20E-010)
peroxisome (52/22; 
0.66E-004)
protein biosynthesis 
(493/168; 0.12E-012)
vitamin metabolism 
(48/20; 0.27E-003)
structural mol act (359 
/119; 0.13E-006)
8 aa_starv_0.5_h aa_starv_1_h aa_starv_2_h aa_starv_4_h
aa_starv_6_h Nitrogen_Depletion_30_min.
Nitrogen_Depletion_1_h Nitrogen_Depletion_2_h
Nitrogen_Depletion_4_h
3.60 #### 4.66 peroxisome (52/6; 
0.14E-003)
plasma membrane (197/
17; 0.35E-006)
aminoacid metab 
(173/42; 0.24E-031)
transporter act (343/27; 
0.12E-004)
lyase activity (97/12; 
0.24E-004)
9 33C_vs._30C_._90_minutes dtt_480_min_dtt.2
steady_state_36_dec_C_ct.2
steady_state_36_dec_C_ct.2_.repeat_hyb._
0.12 -1.42 -0.24
10 dtt_060_min_dtt.2 YP_galactose_vs_reference_pool_car.2
YP_raffinose_vs_reference_pool_car.2
1.43 0.12 -1.53
11 Diauxic_Shift_Timecourse_._0_h
diauxic_shift_timecourse_9.5_h diauxic_shift_timecourse11.5_
2.86 1.16 0.44 vacuole (140/6; 0.63E-
003)
12 YPD_stationary_phase_2_h_ypd.1
YPD_stationary_phase_4_h_ypd.1
-0.39 3.11 2.06 electron transport (14/
1; 0.91E-003)Page 4 of 18
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known to be transcriptionally regulated through the stress
response element (STRE), recognized by Msn2p and
Msn4p [17,18]. Thus, Cluster 1 corresponds largely to a
"core" ESR, induced by a variety of stimuli, including
"early" time points of osmotic stress and "late" time points
of DTT treatment and stationary culture. A relatively late
induction of ESR by DTT has been noted previously, with
suggestions that ESR could be a secondary response to the
exposure of this reducing agent [13]. Conversely, hyperos-
motic shock is known to induce a rapid and strong expres-
sion of ESR [13,15].
Clusters 2 and 16 correspond to responses to three oxidiz-
ing agents: hydrogen peroxide, which generates peroxides
and hydroxyl radicals; menadione, a generator of superox-
ide; and diamide, a thiol reducing agent. FADA groups
together responses to H2O2 and diamide (Cluster 2),
while defining a distinct group for responses to menadi-
one (Cluster 16). It is well known that several organisms
use distinct sensing and response systems to discriminate
among different degrees of oxidative injury. In S. pombe,
reponses to low concentrations of H2O2 and to diamide
depend on the b-Zip transcription factor pap1, while
reponses to higher concentrations of H2O2 utilize a differ-
13 diauxic_shift_timecourse_13.5_h
diauxic_shift_timecourse_15.5_h
YPD_stationary_phase_8_h_ypd.1
-0.51 -0.27 -0.20
14 1M_sorbitol_._60_min 1M_sorbitol_._90_min
1M_sorbitol_._120_min
1.21 2.46 1.33 cell cycle (115/4; 0.11E-
003)
15 YPD_2_h_ypd.2 YPD_4_h_ypd.2 YAP1_overexpression -0.34 0.20 0.56
16 1_mM_Menadione_.10_min.redo
1_mM_Menadione_.20_min._redo
1_mM_Menadione_.30_min._redo
1mM_Menadione_.40_min._redo
1_mM_Menadione_.50_min.redo
1_mM_Menadione_.80_min._redo
1_mM_Menadione_.105_min._redo
1_mM_Menadione_.120_min.redo
1_mM_Menadione_.160_min._redo
4.71 6.25 2.67 mitochondrion (732/88; 
0.49E-003)
Golgi apparatus (90/
17; 0.63E-003)
vesicle-med. Transp. 
(190/31; 0.84E-004)
17 Heat_Shock_000_minutes_hs.2
Heat_Shock_000_minutes_hs.2.1
Heat_Shock_000_minutes_hs.2.2
37C_to_25C_shock_._15_min 37C_to_25C_shock_._30_min
37C_to_25C_shock_._45_min 37C_to_25C_shock_._60_min
37C_to_25C_shock_._90_min dtt_000_min_dtt.2
dtt_015_min_dtt.2 dtt_030_min_dtt.2
steady_state_21_dec_C_ct.2 steady_state_25_dec_C_ct.2
steady_state_29_dec_C_ct.2
5.33 #### 5.49 ribosome (368/145; 
0.26E-007) nucleolus 
(325/138; 0.15E-009)
ribosome biog & ass 
(271/121; 0.87E-011)
RNA metabolism (382/
148; 0.14E-007)
protein biosynthesis 
(493/194 0.12E-010)
structural mol. act. 
(359/123; 0.11E-003)
RNA binding (268/96; 
0.93E-004)
18 YP_fructose_vs_reference_pool_car.2
YP_glucose_vs_reference_pool_car.2
YP_mannose_vs_reference_pool_car.2
YP_sucrose_vs_reference_pool_car.2
2.12 0.31 0.32 mitochondrial membr 
(136/7; 0.59E-004)
19 Hypo.osmotic_shock_._15_min
Hypo.osmotic_shock_._30_min
Hypo.osmotic_shock_._45_min
Hypo.osmotic_shock_._60_min
3.08 5.06 3.67 bud (59/6; 0.40E-003)
nucleolus (325/21; 
0.525E-005)
ribosome biog & ass 
(271/24; 0.12E-007)
RNA metabolism (382/
22; 0.86E-004
20 Heat_Shock_060_minutes_hs.2 NA NA NA
21 17_deg_growth_ct.1 21_deg_growth_ct.1 25_deg_growth_ct.1
29_deg_growth_ct.1
1.67 1.54 -1.34
22 steady_state_15_dec_C_ct.2 steady_state_17_dec_C_ct.2 0.51 -1.14 0.48
23 2.5mM_DTT_005_min_dtt.1 2.5mM_DTT_015_min_dtt.1
2.5mM_DTT_030_min_dtt.1
0.03 1.28 0.32
24 galactose_vs._reference_pool_car.1
glucose_vs._reference_pool_car.1
mannose_vs._reference_pool_car.1
raffinose_vs._reference_pool_car.1
sucrose_vs._reference_pool_car.1 steady_state_33_dec_C_ct.2
8.69 5.93 6.57 cell cortex (39/7; 0.97E-
003)
cytoplasmic vesicle (52/
11; 0.15E-004)
bud (59/10; 0.27E-003)
endomembrane syst 
(76/15; 0.21E-005)
cytokinesis (52/10; 
0.25E-003)
nuclear org & biog 
(105/16; 0.20E-003)
vesicle-med transp 
(190/23; 0.55E-003)
helicase activity (71/13; 
0.21E-004)
25 29C_to_33C_._30_minutes
29C_.1M_sorbitol_to_33C_._1M_sorbitol_._30_minutes
29C_.1M_sorbitol_to_33C_._.NO_sorbitol_._15_minute
29C_.1M_sorbitol_to_33C_._.NO_sorbitol_._30_minute
Hypo.osmotic_shock_._5_min steady.state_1M_sorbitol
0.39 2.96 3.27 DNA metabolism (221/
8; 0.78E-003)
DNA binding (146/7; 
0.21E-003)
26 Heat_Shock_005_minutes_hs.2 NA NA NA
(a) GO terms discussed in the text are shown in bold. Together with each GO term, we show the number of genes corresponding to that term; the 
number of genes of that term in the cluster; and the corresponding P-value, according to the hipergeometric distribution.
(b) NA: Data Not Available. No significant genes (according to the q-value cutoff) could be found.
Table 1: Results of the analysis of the yeast dataset [13]. The different clusters found by FADA are shown, together with the significant 
GO terms associated to them. The samples belonging to each one of the clusters are also shown. The first column shows the cluster 
number; the second shows the conditions associated to that cluster; columns 3 to 5 show the Z-score of the GO terms associated to 
the cluster (see Methods) at the Cellular Component (CC), Biological Process (BP) and Molecular Function (MF) levels; columns 6 to 
8 show the corresponding GO terms. (Continued)Page 5 of 18
(page number not for citation purposes)
BMC Genomics 2005, 6:109 http://www.biomedcentral.com/1471-2164/6/109ent transcription factor, atf1 [19]. The S. cerevisiae homo-
logue of S. pombe pap1 is Yap1p, a transcription factor
regulated by oxidation, formation of intramolecular
disulfide bonds at its carboxy terminus and nuclear trans-
location upon exposure to H2O2 and diamide [20-22]. On
the other hand, of the b-ZIP proteins in S. cerevisiae,
Yap3p is most similar to atf1 in its carboxy terminus, sug-
gesting that both atf1 and Yap3p could be subject to a sim-
ilar redox regulation. Interestingly, YAP1 is upregulated in
Cluster 2 (H2O2 and diamide), but not in Cluster 8
(menadione), while Yap3 is upregulated in the latter Clus-
ter (Table 1 of Supplementary Data). Moreover, several of
the genes most relevant to Cluster 2 are known to respond
to mild oxidative stress, and are controlled by Yap1p [23].
The statistically significant GO-terms selected are related
to "oxidoreductase" and "peptidase" activities. This includes
genes regulating the thioredoxin and glutathione biosyn-
thesis, genes for heat shock proteins, and a large number
of genes involved in proteasome function and ubiquitin-
dependent protein degradation (Table 1 of Supplemen-
tary Material).
Cluster 6 includes cultures at late times of nitrogen starva-
tion. Many of the relevant genes in this group code for
enzymes for the utilization and enhanced transport of
poor nitrogen sources, such as allantoin or urea (Table 1
of Supplementary Material). Other upregulated genes
include those required for different stages of meiosis
(chromosome pairing, recombination and segregation;
anaphase; or nucleokinesis), sporulation, autophagy, or
genes that regulate vesicle and peroxisome structure and
dynamics. Among these genes are also transcriptional reg-
ulators with major roles in the control of several of these
processes, such as UGA3, DAL81 (allantoin metabolism),
or IME1, RIM101 and SPO1 (meiosis and sporulation).
This is consistent with the development of a classical
response to nitrogen starvation in the absence of fer-
mentable carbon sources, which leads to meiosis and
sporulation [24-27]. FADA also suggests that this response
to nitrogen starvation becomes most prominent at rela-
tively late times, when it can be distinguished from the
early, relatively non-specific response to nutrient depriva-
tion [25,26]. In fact, FADA finds "transcription" and "sporu-
lation" as significant GO-terms (Table 1).
Cluster 8 aggregates samples from early stages of both
early response to aminoacid and nitrogen starvation.
FADA finds a significant overrepresentation of genes for
amino acid biosynthetic pathways (Table 1), consistent
with the fact that deprivation of nutrients, including nitro-
gen and carbon sources, is recognized by several sensing
systems regulating rapamycin-sensitive TOR kinase [28].
This lipid-dependent kinase derepresses translation of the
GATA transcription factor Gcn4p [29,30], which controls
expression of many genes, including enzymes involved in
amino acid biosynthesis [31]. Thus, the selection of genes
in Cluster 8 is consistent with known Gcn4p-dependent
responses to nutrient and nitrogen starvation [31].
Altogether, these results indicate that the automatic anal-
ysis provided by FADA yields results consistent with the
known biochemistry of yeast.
Application of FADA to the prostate cancer dataset
We next applied FADA to the dataset published by Welsh
et al. [14], for the analysis of transcripts associated with
prostate cancer. Samples were classified into two major
branches: samples from cultured cells, and samples from
tissues, which in turn could be further bifurcated into two
well-supported branches, one corresponding to samples
enriched for carcinomatous cells and one for non-neo-
plastic prostate cells (Figure 2). The first-level grouping
into cultured vs. non-cultured samples most likely reflects
the profound impact of culturing procedures on the tran-
scriptional profiles of the different cell types. Within the
cultured cells subgroup, samples were generally clustered
according to cell type, with haematopoietic cell lines
forming well-clustered groups and epithelial and fibrob-
lastic prostate-derived cells clustering together with
endothelial cells. A separate cluster was formed by the
androgen-sensitive epithelial cell line LNCaP, the prostate
cancer cell lines included in the study. The genes most sig-
nificantly contributing to each sample cluster were ana-
lyzed for their participation in the pathways contained
both in GenMAPP [32], and GO (Tables 2 and 3). Since
pathway categorization is a difficult problem, as partition
of the global interaction network in "parts" inevitably
introduces artefacts, we also proceeded to a detailed, gene-
by-gene inspection of the most discriminative genes based
on inspection of literature data.
Cluster 1 corresponds to the LNCaP cluster. It is placed in
a branch distinctly separated from the rest of the cultured
prostatic cells. LNCaP cells were originally derived from
metastatic prostate cells, presumably of epithelial origin
[33] and respond to androgens through its cognate recep-
tor [34]. FADA found significant overrepresentation of
upregulated genes coding for proteins that participate in
electron transport and ATP generation, both when using
GenMAPP and GO annotations (Figure 3, 4 and Table 2).
Other sets of genes likely relevant to the LNCaP cluster,
but not highlighted in the pathway mapping protocol, are
those for proteins in steroid metabolism and signalling,
such UDP glycosyltransferases B15 (Table 2 of the Sup-
porting Information). Cluster 2 includes mesenchimal,
epithelial, and endothelial cells. This cluster shows a bias
for genes and pathways involved in ubiquitin and protea-
some-dependent protein degradation, cell cycle regula-
tion, inflammatory responses and cell-matrix interaction.
Cluster 3 (hematopoietic cells) showed a significant biasPage 6 of 18
(page number not for citation purposes)
BMC Genomics 2005, 6:109 http://www.biomedcentral.com/1471-2164/6/109Dendrogram for the Welsh dataset [14]Figure 2
Dendrogram for the Welsh dataset [14]. The dashed line indicates the thresholding used to define the clusters.
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BMC Genomics 2005, 6:109 http://www.biomedcentral.com/1471-2164/6/109in genes and pathways involved in cell cycle regulation
and RNA processing. The selected genes included known
markers of differentiation of B cell, T cell or myelomono-
cytic lineages. Examples are genes for immunoglobulin,
histocompatibility antigens, haematopoietic-specific
cytokines and their receptors, and regulatory proteins
known to play significant roles in such lineages in proc-
esses such as signal transduction or cytoskeletal dynamics.
Regarding Cluster 4 (prostate tumor tissue), GenMAPP
mapping finds significant overexpression of enzymes
related to fatty acid metabolism (Table 2). Other genes
and KEGG pathways with a significantly biased associa-
tion with cluster 4 are those for ribosomal function and
fatty acid synthesis (Table 2 of the Supporting Informa-
tion). The upregulation of these two functions in prostate
cancer has been noted previously [14,35]. In addition, GO
mapping finds overrepresentation of genes for proteins
directly involved in steroid receptor recognition, includ-
ing androgen receptor and estrogen receptor β. This is
confirmed by a survey of the list of selected genes, where
one can find a number of proteins involved in steroid sig-
nalling, including the coactivators GRIP1 and NRIP1, and
genes that have been described as transcriptional targets
of these pathways [36], such as the secreted proteases
KLK2 and KLK3, and protein IQGAP, involved in cytoskel-
etal dynamics [37], or the enzymes fatty acid CoA-ligase
or androgen-regulated short chain dehydrogenase (Table
2 of the Supporting Information). A second group of
genes significantly contributing to this cluster are those
for cell surface polypeptide growth factor receptors, asso-
ciated signalling molecules and regulators, and known
transcriptional targets for these pathways. These include
the receptor tyrosine kinase partner ERBB3 (HER3), the
Table 2: Results of the analysis of the Welsh dataset for up-regulated genes. The different sample clusters found by FADA are shown, 
together with the significant GO and GenMAPP terms associated to them. The first column shows the cluster number; the second 
shows the samples associated to that cluster; columns 3 and 4 show the z-score of the GenMAPP and GO terms associated to the 
cluster (see Methods); columns 5 to 8 show the corresponding GenMAPP and GO terms selected.
C SAMPLES Z(GM) Z(GO) GENMAPP GO(MF) GO(BP) GO(CC)
1 LNCaP_A, LNCaP_B, 
LNCaP_+_DHT
7.22 5.09
-0.39
2.59
RNA_transcription_React. 
(2.40e-03)
Electron_Transport_Chain 
(5.74e-10)
oxidoreductase activity 
(1.58e-04)
carrier activity (1.87e-04)
ATPase activity, coupled to 
transmembrane movement 
of substances (4.23e-03)
transcriptional activator 
activity (2.09e-03)
intracellular organelle (5.48e-
04)
2 CAF_1598, BPHF_1598
CAF_1303, CAF_1852
PrSC_A, PrSC_B, CAF_2585, 
Du145, PC3, HUVEC_A, 
HUVEC_B, hPr1, PrEC
3.83 4.66
2.74
5.13
Hypertrophy_model (8.97e-
03)
Proteasome_Degradation 
(1.44e-08)
Cell_cycle_KEGG (7.86e-03)
Pentose_Phosphate_Pathway 
(4.89e-03)
Enzyme inhibitor activity 
(4.96e-04)
hydrolase activity (9.26e-03)
small protein conjugating 
enzyme activity (3.54e-04)
structural constituent of 
cytoskeleton (2.73e-03)
nucleotide binding (1.17e-05)
regulation of cellular process 
(4.31e-03)
cellular physiological process 
(1.93e-04)
signalosome complex (7.27e-
03)
membrane coat adaptor 
complex (4.24e-03)
tubulin (5.06e-06)
proteasome complex (sensu 
Eukaryota)(3.69e-07)
Arp2/3 protein complex 
(4.19e-05)
3 B_CELLS_A, B_CELLS_B 
B_CELLS_C, MOLT4, HL60
4.27 0.42
0.18
-0.04
mRNA_processing_React. 
(2.10e-03)
G1_to_S_cell_cycle_React. 
(9.25e-05)
Cell_cycle_KEGG (1.94e-04)
Small_ligand_GPCRs (5.52e-
03)
Ovarian_Infertility_Genes 
(5.19e-03)
GPCRDB_Class_C_Metabot
ropic_glutamate_pheromone 
(4.72e-04)
4 T4, T7 T3, T5, T1, T27, T10, 
T9, T13A, T13B, T22, T12, 
T29, T8, T31, T30, T26, T19, 
T16, T23, T6, T24, T21, T11, 
T17
2.06 1.93
0.39
0.76
Fatty_Acid_Degradation 
(8.48e-03)
Hypertrophy_model (3.34e-
03)
Eicosanoid_Synthesis (3.56e-
03)
steroid binding (7.57e-03)
isomerase activity (7.99e-04)
vitamin binding (6.99e-04)
5 N2, N1, N5, N3, N9, N8, N7, 
N10, N4
6.86 2.52
-0.31
-0.40
Smooth_muscle_contraction 
(6.55e-03)
Calcium_reg_in_card_cells 
(3.97e-03)
channel or pore class 
transporter activity (1.75e-
03)
structural constituent of 
cytoskeleton (2.75e-04)
(a) GO or GenMAPP terms are discussed in the text. Together with each term, we show the corresponding P-value, according to the 
hipergeometric distribution (see Methods).
(b) The Z(GO) column shows the Z-scores corresponding to Molecular Function (MF), Biological Process (BP), and Celular Component (CC), 
respectively, obtained for each cluster. The Z(GM) column refers to the Z-score corresponding to the GenMAPP terms.Page 8 of 18
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BMC Genomics 2005, 6:109 http://www.biomedcentral.com/1471-2164/6/109calmodulin-dependent kinase activator CAMKK2, or the
signalling modulators RAPGA1 and PDE3B (Table 2 of
the Supporting Information).
Finally, the highest ranking genes for samples from nor-
mal prostate tissue (Cluster 5) correspond, according to
GO, to proteins involved in the control of cytoskeletal
architecture and dynamics in muscle cells (Table 2). Gen-
MAPP finds a significant overrepresentation of muscle-
associated functions. The implication is that, in these
experiments, normal prostate tissue samples possibly are
strongly enriched for muscle cells. This strong overrepre-
sentation of genes corresponding to a smooth muscle
phenotype suggests that the non-neoplastic tissues used
correspond to areas of prostate hyperplasia or adenoma
derived from the transition zone, in which smooth muscle
cells are often major contributors [38]. In practical terms,
this suggests that these experiments may be used with cau-
tion in the comparison of tumor epithelial cells with cor-
responding normal epithelial counterparts.
In recent years, several transcriptional profiling studies
have been performed in prostate cancer, aimed at the
identification of novel tumor markers [14,39-41] or prog-
nostic signatures [42-44]. So far, only one study has
systematically searched for overrepresented biochemical
pathways in a meta-analysis of four previously published
prostate cancer transcriptional profiling studies [45]. This
study used KEGG as reference pathway database, which is
biased towards metabolic pathways [46]. Our study, how-
ever, focuses on GenMapp and GO terms, and therefore
on the identification of signalling pathways.
Signalling pathways in prostate cancer and their 
experimental validation
In order to validate the pathways found to be overrepre-
sented in prostate tumor samples, we used real-time RT-
PCR. We chose for our analysis the genes for hepsin, KLK3
(PSA), ERBB3 (HER3), IQGAP2, and POR/ARFAPTIN2.
Hepsin was found to be overexpressed in most tumor
samples, and validated by immunohistochemical analysis
[14]. This gene has been shown to be overexpressed in
prostate cancer by several other groups. KLK3 (PSA) is the
Table 3: Results of the analysis of the Welsh dataset for down-regulated genes. The different sample clusters found by FADA are 
shown, together with the significant GO and GenMAPP terms associated to them. The first column shows the cluster number; the 
second shows the samples associated to that cluster; columns 3 and 4 show the Z-score of the GenMAPP and GO terms associated to 
the cluster (see Methods); columns 5 to 8 show the corresponding GenMAPP and GO terms selected.
C SAMPLES Z(GM) Z(GO) GENMAPP GO(MF) GO(BP) GO(CC)
1 LNCaP_A, LNCaP_B, 
LNCaP_+_DHT
0.36 -0.10
-0.54
4.09
extracellular space (3.74e-
04)
MHC protein complex 
(4.71e-04)
2 CAF_1598, BPHF_1598, 
CAF_1303, CAF_1852, PrSC_A, 
PrSC_B, CAF_2585, Du145, 
PC3, HUVEC_A, HUVEC_B, 
hPr1, PrEC
2.33 2.43
0.68
-0.50
Hs_GPCRDB_Other 
(1.96e-03)
Hs_Ribosomal_Proteins 
(1.03e-08)
structural constituent of 
ribosome (2.57e-05)
SH3/SH2 adaptor activity 
(6.48e-03)
nucleic acid binding (7.71e-
04)
oxygen transporter activity 
(6.93e-03)
nucleobase, nucleoside, 
nucleotide and nucleic acid 
transporter activity (6.93e-
03)
3 B_CELLS_A, B_CELLS_B, 
B_CELLS_C, MOLT4, HL60
0.91 0.85
-0.65
-0.91
4 T4, T7, T3, T5, T1, T27, T10, T9, 
T13A, T13B, T22, T12, T29, T8, 
T31, T30, T26, T19, T16, T23, 
T6, T24, T21, T11, T17
4.30 1.04
1.86
7.71
G1_to_S_cell_cycle_React 
(7.76e-04)
Glycolysis_and_Gluconeoge
nesis (4.02e-04)
Cell_cycle_KEGG (7.03e-
08)
DNA_replication_Reactom
e (2.01e-03)
signalosome complex 
(5.23e-04)
intracellular (4.66e-04)
tubulin (2.97e-03)
proteasome complex (sensu 
Eukaryota) (2.47e-04)
proton-transporting ATP 
synthase complex (9.01e-
04)
Arp2/3 protein complex 
(5.23e-04)
5 N2, N1, N5, N3, N9, N8, N7, 
N10, N4
-0.21 -0.65
3.83
-0.53
metabolism (3.90e-04)
(a) GO or GenMAPP terms are discussed in the text. Together with each term, we show the corresponding P-value, according to the hipergeometric 
distribution (see Methods).
(b) The Z(GO) column shows the Z-scores corresponding to Molecular Function (MF), Biological Process (BP), and Cellular Component (CC), 
respectively, obtained for each cluster. The Z(GM) column refers to the Z-score corresponding to the GenMAPP terms.Page 9 of 18
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BMC Genomics 2005, 6:109 http://www.biomedcentral.com/1471-2164/6/109Expression levels for the 20 most relevant genes selected in each cluster for the Welsh datasetFigure 3
Expression levels for the 20 most relevant genes selected in each cluster for the Welsh dataset. Gene descriptions can be 
found in Table 2 of the Supporting Information. A) (See Figure 3) Up-regulated; B) Down-regulated. (See Figure 4)
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BMC Genomics 2005, 6:109 http://www.biomedcentral.com/1471-2164/6/109marker par excellence of prostate epithelial activity and cel-
lular bulk, and detection of its serum protein levels is the
best available marker for monitoring prostate cancer [47].
HER3 is a receptor for the paracrine growth factor neregu-
lin-1, and a transmembrane protein that tethers the ligand
to its dimerization partners, the receptor tyrosine kinases
HER2 and HER4 [48], and known to play important roles
in the development and progression of the malignant
phenotype in breast cancer [49]. The abnormal expression
and activity of HER2 has been studied extensively in the
context of prostate cancer [50], being found overexpressed
in advanced tumors, either metastatic or homone-inde-
pendent, but infrequently in primary, organ-confined
tumors. More controversial is the information available
on the role of HER3, with reports of its overexpression in
prostate cancer together with HER2, HER4, or both
[51,52], but also of its overexpression only in metastatic
tumors, in particular of a truncated form corresponding to
the extracellular domains of HER3 [53]. Furthermore, sev-
eral transcriptional profiling analyses have found overex-
pression of this gene in prostate cancer. IQGAP2 is a
calmodulin-binding protein that participates in cell sig-
nalling and modulation of cytoskeletal dynamics [37],
and its activity has been reported to be positively [54] and
negatively associated with neoplastic phenotype. POR1/
ARFAPTIN2, a Rac1-interacting protein [55], is a regulator
of cytoskeletal dynamics that so far has not been associ-
ated with any particular type of neoplasia.
The results of semiquantitative real-time RT-PCR on our
samples indicate that hepsin is significantly overexpressed
in 14 out of 14 cases, IQGAP2 in 8 of 14, and HER3 in 10
of 14 cases (Figure 5). Other genes analyzed, such as KLK3
(PSA), HER2 or the steroid receptors androgen receptor,
estrogen receptor α or estrogen receptor β are less fre-
quently overexpressed in these tumors. Levels of desmin
transcripts were determined as an index of the contribu-
tion of stromal cells, suggesting that the overexpression of
the analyzed genes are detected in tumor samples even in
the presence of substantial stromal contamination (Figure
5). Of particular interest is the observed upregulation of
HER3 in prostate tumor tissues relative to normal tissues.
The HER3/ErbB3 protein has impaired intrinsic kinase
activity [56], and it appears to function in signal transduc-
tion by tethering the ligand to other members of the HER
family of receptors, with preference for HER2/ErbB2 [57].
Increased levels of expression of HER3 are seen in many
tumors that express HER2 [58], and it is widely assumed
that the signalling and/or oncogenic functions reside in
the corresponding heterodimer, rather than in either indi-
vidual receptor [59,60]. Recent experimental evidence fur-
ther highlights the importance of HER3 in conferring a
malignant phenotype and a hormone-refractory state to
prostate epithelial cells [61]. Thus, whenever HER3 is
expressed it is reasonable to expect co-expression of at
least one other member of the HER family. Therefore, we
determined by real-time RT-PCR the relative expression in
our prostate tissue samples of the genes for all four mem-
bers of the HER family of receptor tyrosine kinases. Our
results show that HER4 is expressed at increased levels in
10 of 14 prostate tumor samples (Fig. 5A, B), whereas
HER2/ErbB2 and EGFR are overexpressed in 3 of the 14
samples analyzed. Seven samples simultaneously overex-
pressed HER3 and HER4, of which 2 overexpressed all
four members of the HER family (Fig. 5A, B). None of the
samples overexpressed the pairs HER3 and HER2, or
HER3 and EGFR, without overexpressing at the same time
one of the other members of the family (Fig. 5A, B).
As mentioned in the Methods section, both tumor and
normal tissues were carefully chosen to have similar rep-
resentation of epithelial compartment. However, to fur-
ther ensure that the observed expression of HER3 was not
due to a dilution effect of normal epithelial cells by
stroma, we performed real-time PCR analysis of laser
microdissected samples. For this, we selected four samples
that had shown overexpression of HER3 in the enriched
tumor samples described above, and two that had levels
that did not differ significantly from non-tumor contain-
ing (normal) matched tissues. Of the four samples in
which the enriched tumor tissue had shown increased lev-
els of HER3 transcript, three microdissected samples over-
expressed HER3 (Fig. 5C). In two of the microdissected
samples, HER3 transcript levels were equal in normal and
tumor microdissected epithelia, and this also corre-
sponded to samples in which HER3 levels did not differ
significantly between enriched tumor and normal pros-
tate tissues (Fig. 5C). This analysis showed that overex-
pression of HER3 in prostate tumor tissues is not due to
simple enrichment of epithelial cells in comparison with
non-tumor tissues. To further confirm the cell type
expressing HER3 in prostate tissues,
immunohistochemical analysis with a monoclonal anti-
body to HER3 was performed on 16 prostate samples,
arranged in duplicate 1-mm diameter cores in tissue
microarrays, in which both tumor and normal glands
were present. HER3 protein was found clearly overex-
pressed in tumor epithelia in 13 of the 16 cases (81.2%),
showing juxtamembrane and finely granular cytoplasmic
patterns (Fig. 5D). In all cases, normal epithelia showed
weak reactivities for HER3 (Fig. 5D).
In summary, our transcriptome re-analysis, validated by
real-time RT-PCR of non-microdissected and microdis-
sected samples and by immunohistochemical analysis,
significantly reinforces previous immunohistochemical
studies that reported high levels of expression of HER3
and HER4 in primary prostate cancer [51,52].Page 11 of 18
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BMC Genomics 2005, 6:109 http://www.biomedcentral.com/1471-2164/6/109Validation of genes selected by FADA from the Welsh et al. dataset [14] as overexpressed in prostate cancerFigure 5
Validation of genes selected by FADA from the Welsh et al. dataset [14] as overexpressed in prostate cancer. (A) RT-PCR was 
applied to 14 paired prostate tumor – normal prostate samples to determine the expression levels of a selection of genes 
shown by FADA as significantly overrepresented in prostate cancer (HPN, KLK3, IQGAP2, POR1 and HER3), and additional 
genes relevant to this tumor (genes for the receptor tyrosine kinases EGFR, HER2, HER4, and genes for the steroid hormone 
receptors AR, ERα and ERβ). The expression values for each gene, previously normalized with respect to the S14r expression 
level in each sample, are shown as ratios of the normalized values in prostate cancer vs. values in the matching normal prostate 
tissue. Quantitation of desmin expression levels was used to assess the degree of contribution of stromal components in the 
samples analyzed. Values equal to or above 100-fold are shown as 100. (B) Heatmap representation of the same data (color 
scale as shown below). (C) Real-time PCR analysis for HER3 transcript levels of laser microdissected tumor and normal sam-
ples, compared with relative transcript levels in enriched (non-microdissected) tissues from the same cases. (D) Immunohisto-
chemical analysis of HER3 on paraffin-embedded prostate tissue sections arranged in tissue microarrays (see Methods). Left, 
low magnification image (×100) of one case, with weak staining for HER3 in normal glands (n), and a strong staining in tumor 
epithelial cells (t). Right, higher magnification (×400) of a second case.Page 13 of 18
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We have shown that the method presented here for the
analysis of expression microarray data permits the classifi-
cation of samples into meaningful categories and, simul-
taneously, to identify a subset of genes and their
assignment to pathways most significantly contributing to
the corresponding phenotypes, while allowing for a given
gene to participate as significant in more than one cluster
of samples. The analysis of the yeast dataset validates the
approach. Our results are consistent with biochemical
pathways known to be activated in the different stress con-
ditions analyzed, and the clustering of samples reflects the
underlying similarity of the biochemical responses. In the
application to the prostate cancer dataset, we have found
that two pathways, one modulated by androgen receptor
and a second one by signals that originate from cell sur-
face growth factor receptors, are prominently active in the
organ-confined, non-metastatic prostate cancer samples
analyzed. The latter pathway has been reported to be spu-
riously active in at least a subset of prostate tumors that
have progressed to invasive and hormone-independent
states [62]. Our results suggest that such altered activation
may already be present in primary tumors. Although a
prevailing model for prostate tumor progression is that
acquisition of the capacity for metastatic and hormone
independent growth proceeds through selection of rare
populations of cells concealed among primary tumor
cells, there is also evidence that a transcriptional program
for metastasis may already be present in the bulk of pri-
mary tumors at the time of diagnosis [63,64]. Our analysis
would be more consistent with the latter model.
Finally, we have unveiled and validated several markers
highlighted by the analysis of the prostate cancer dataset.
While several of these genes were identified in the original
analysis of the data [14], others are revealed here, notably
HER3, IQGAP2 and POR1, the biologically most relevant
being HER3. With an external dataset, we have found that
prostate cancer samples frequently co-overexpress HER3
and HER4, accompanied less frequently by increased
expression of EGFR or HER2. Overexpression of HER2
and consequent increased signalling have been associated
with advanced prostate cancer, development of hormone
independent state and poor prognosis [65,66], but is
infrequently observed in primary tumors [67,68]. On the
other hand, our results suggest that, in primary prostate
cancer, HER3, together or not with HER4, rather than
receptor complexes involving HER2, could play impor-
tant roles in the biology of these tumors.
Materials and methods
Datasets
The S. cereviseae dataset consists of transcriptional
responses of the yeast S. cerevisiae to environmental stress
[13]. It originally consists of spotted array measurements
of 6152 genes in 173 experimental conditions that
include temperature shocks, hyper and hypoosmotic
shocks, exposure to various agents such as peroxide,
menadione, diamide, dithiothreitol, amino acid starva-
tion, nitrogen source depletion and progression into sta-
tionary phase. Log-ratios were preprocessed following
several steps: first data from genes with missing values
were filtered out, and their missing values estimated with
LSimpute [69] using the 'Adaptive' method. Next, ratios
were computed from the log-ratios and quantile-normal-
ized (experiment-wise) using the normalizeQuantile
function from the R package [70], so that all experiments
had the same average sample distribution. Finally, ratios
were log transformed again.
The prostate cancer dataset chosen is described in [14]. It
was originally obtained by hybridizations on Affymetrix
U95A oligonuleotide arrays with probes for a total of 55
samples. Intensity values were preprocessed following
several steps: first intensity data were thresholded, with
intensities below 10 fixed at 10 and values above 16000
fixed at 16000. The thresholded values were log-trans-
formed and then centered by the median of all experi-
ments. Finally, genes were subjected to z-transformation
(per gene basis).
Determination of genotypically coherent groups of 
samples
Q-mode Factor Analysis (FA) [9] seeks to find an underly-
ing orthogonal factor model of an original X-matrix nxm
(where n are the number of samples and m the number of
mRNA levels measured) of the form:
X = LF + E
L is the loadings matrix of size nxk, where k is the number
of factors, and F the scores matrix of size kxm, while E is the
residual matrix, which contains both the specific variance
of the individual genes and the errors in the model (see
Figure 1). We used the so-called principal factor solution to
solve this factor model. Specifically, in a first step, and
based on the correlation matrix R derived from X, com-
munalities (i.e. the proportion of the variance explained
by common factors) were computed from the multiple
squared correlation coefficient between the ith variable
and the rest. These communalities replaced the diagonal
entries of the correlation matrix, which was subjected to
diagonalization. New communalities were computed
from the loadings at the chosen dimensionality, obtained
by scaling the eigenvector matrix (P), as follows:
L = P Λ1/2
The new communalities again replaced the diagonal
entries, and the process was iterated until convergence.Page 14 of 18
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means of a varimax rotation [9]. The effect of this rotation
is to maximally align each of the samples with one factor
in order to simplify the factor model and make it more
readily interpretable. Phyletic trees were derived by clus-
tering samples in loadings space at the optimal dimen-
sionality using average linkage [4,11]. When needed,
bootstrap values were computed by selecting random sub-
sets of 90% of the genes [71]. Distribution of trees and fre-
quency of each branch in the original tree were recorded
using CONSENSE, program included in the PHYLIP pack-
age [72].
Selecting genes associated to each cluster
Once sample clusters are defined, these are used to iden-
tify groups of genes contributing heavily to the specific
character of different groups. Each gene on the list is sub-
jected to a Student's t-test that measures the differential
expression of the gene in the cluster as compared with the
rest of the samples. t-test scores were transformed to q-val-
ues, which include multiple testing correction. The q-
value is similar to the well known P-value, except that it is
a measure of significance in terms of the false discovery
rate, rather than the false positive rate [73]. Genes with a
q-value < 10-4 were taken as differentially expressed for
that particular cluster.
Assigning pathways to gene clusters
The association between selected genes and biological
functions was established by determining the hypergeo-
metric distribution of genes on the annotation databases
GO [12] or GenMapp [32]. With this distribution we com-
puted the probability that at least x genes annotated
within a given biological function according to GO (or
GenMapp) in a cluster of size n (the total number of genes
per cluster selected in the previous step) can be obtained
by chance, given a population of N genes under consider-
ation and given A, the total number of genes within N
with that particular annotation. These P-values are
obtained according to:
An aggregated score for each cluster from the significant P-
values (i.e., those below 10-2) is computed as follows:
s0 = ∑-ln p(x; N, A, n)
The significance of this score is established by simulation.
We randomly selected 100 samples of size n genes each
(the number of genes per cluster selected according to the
q-value) and computed a new s-score (sr) for each one. The
Z-score is finally computed as:
z = (so - <sr>)/σr
Z-scores > 2.0 are taken as indicative of significant associ-
ation between the samples in the cluster and the set of
pathways uncovered.
We should emphasize that in spite of the apparent intri-
cacy of the computational procedure, the computational
complexity is similar to other biclustering methods, and
operates within a highly constrained parameter space: in
the factor analysis part of the program only the percentage
of variance employed should be set, yielding a reduced
number of dimensions or latent variables, usually below
5; the number of clusters is automatically determined in
this space from the c-index, and has no free parameters,
and the selection of genes relevant for each cluster only
depends on the cutoff employed in the q-value.
Real-time RT-PCR
We used RT-PCR with either TaqMan probes or by
SYBRGreen incorporation to determine the expression
levels of selected genes on samples unrelated to the origi-
nal study by Welsh et al. In each instance, the tumor sam-
ple and its matching normal counterpart were obtained
from the same case, upon removal by radical prostatec-
tomy. Serial sections from all normal counterparts to the
tumor tissues were stained and analyzed to confirm that
normal prostate glands and epithelial cells were present in
near-normal patterns, and that they contained less than
1% of cells or structures with carcinomatous appearance.
In addition, samples were chosen such that the tumor and
normal counterparts in each case had approximately
equal representations of the epithelial compartment, as
assessed microscopically. RNA was isolated from corre-
sponding frozen serial sections, and controlled for quality
on a 2100 BioAnalyzer instrument (Agilent, Palo Alto,
CA). For each sample, 0.5 µg of total RNA was reverse
transcribed by priming with random hexamers at 42°C
for 50 minutes, followed by treatment with RNase at
37°C for 20 min. The resulting cDNAs were used as tem-
plates in PCR reactions with gene-specific primers. Real-
time PCR was performed on ABI PRISM 7700 (Applied
Biosystems, Foster City, CA) or DNA Engine Opticon (MJ
Research, Waltham, MA) instruments. TaqMan probes
and their corresponding primer sets were obtained from
Applied Biosystems. Thermal cycler conditions were 95°C
for 10 min and 40 cycles of 95°C for 15 sec and 60°C for
1 minute for TaqMan assays. In the case of SYBRGreen
reactions, the conditions were 95°C for 15 min, and 40
cycles of 95°C for 15 sec, 55°C for 30 sec and 72°C for 30
sec. All determinations were performed in triplicate and in
at least two independent experiments. Since the relative
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were found to be approximately equal, the ∆∆Ct method
was applied to estimate relative transcript levels. Levels of
ribosomal S14r amplification were used as an endog-
enous reference to normalize each sample value of Ct
(threshold cycle) and normal tissues were used as calibra-
tors for their tumoral counterparts in each case. The final
results, expressed as n-fold differences in target gene
expression were calculated as follows:
nTARGET = 2-[(Ct target - Ct reference)TUMORAL - (Ct target - Ct
reference)NORMAL]
Laser capture microdissection
Prostate tissues were obtained by punch sections of radi-
cal prostatectomies and snap-frozen in isopentane at -
50°C embedded in OCT-containing cryomolds. 8 µM cry-
osections were mounted onto plastic membrane-covered
glass slides (PALM Mikrolaser Technology, Bernried, Ger-
many), fixed for 3 minutes in 70% ethanol, stained with
Mayer's hematoxilin, dehydrated, air-dried for 10 minutes
and stored at -80°C until used. Laser catapulting micro-
dissection was performed with a PALM MicroBeam Sys-
tems instrument. 2 to 5 × 104 normal or carcinomatous
epithelial cells were collected and estimated to be >99%
homogeneous by microscopic visualization.
Total RNA from microdissected samples was isolated
using the PicoPure RNA Kit (Arcturus Engineering, Santa
Clara, CA), with an additional DNase I digestion step
(Qiagen, Valencia, CA).
Immunohistochemistry
Sixteen paraffin embedded prostate samples were evalu-
ated for HER3 expression by immunohistochemistry on a
tissue microarray. The cases were represented in dupli-
cated 1-mm diameter cores and always included normal
prostatic glands adjacent to neoplastic foci in at least one
of the cores. Three µM sections of the microarray were
deparaffinized, rehydrated and subjected to antigen
retrieval in a pressure cooker with citrate buffer at pH 6.0
for 5 min. Slides were cooled for 15 min, washed in water
and incubated overnight at 4°C with anti-HER3 mouse
monoclonal antibody (Upstate Biotechnology, Lake
Placid, New York). Endogenous peroxidase was quenched
and slides were incubated for 30 minutes with secondary
antibody (Envision, DAKO, Gostrup, Denmark). Reac-
tions were detected after development with diaminoben-
cidine and H2O2 for 3 min. Slides were counterstained
with Harri's hematoxilin, dehydrated and mounted. As a
negative control, the primary antibody was substituted for
isotype-matched mouse IgG.
Access to the program
The complete procedure has been coded in a Fortran-77
program, called FADA. Remote access to the program has
been enabled by setting up a web-server where the pro-
gram can be executed [74].
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